Category: Ovarian cancer

Do you have ovarian cancer from Talcum Powder? Get an ovarian cancer lawyer for a Talcum Powder lawsuit.

Alternatives To Talcum Powder

Talcum Powder Lawsuit Helpline continues to get calls on a daily basis from women with a diagnosis of ovarian cancer seeking a Talcum Powder lawyer. The Talcum Powder Lawsuit Helpline offers the latest news on Talcum Powder and the Talc Lawsuits. We found this article online about alternatives to talcum powder and think it will be helpful to our readers.

What Are The Alternatives To Talcum Powder?

Not all medical professionals agree that a link between baby powder and ovarian cancer exists.
The recent headlines about baby powder and its connection to ovarian cancer may raise more questions than answers. In February, a Missouri court ordered Johnson & Johnson to pay $72 million in damages to the family of Jackie Fox, a woman who died of ovarian cancer. The lawsuit said her death was linked to her 50-year daily habit of applying baby powder. But Johnson & Johnson insisted a correlation between talc powder and ovarian cancer has not been proven.

“The verdict goes against decades of sound science proving the safety of talc as a cosmetic ingredient in multiple products, and while we sympathize with the family of the plaintiff, we strongly disagree with the outcome,” a spokesman for the company said in a statement.

Prosecutors say Johnson & Johnson knew about the risk since the early 1980s and did not protect its customers. In fact, the first study conducted on talc powder use on female genitalia found a 92 percent increased risk for ovarian cancer with women who reported genital talc use. But still, other doctors disagree. “Several decades of medical research do not support the hypothesis that use of talcum powder causes ovarian cancer,” said Dr. Hal Lawrence, chief executive officer of the American Congress of Obstetricians and Gynecologists.

If all this back-and-forth has you questioning your baby powder usage, fear not. There are some safe alternatives to talc powder:

Cornstarch. Found in the baking aisle of your local grocery store, cornstarch is a great natural alternative to talc. The consistency is exactly the same, so it’ll help soak up wetness just as well. Cornstarch is derived from the endosperm of a corn kernel and is often used to help thicken sauces.

Arrowroot starch or tapioca starch. Both staples in a paleo baker’s kitchen, these starches are all-natural alternatives to talc. Arrowroot is derived from several tropical South American plants. Tapioca starch is derived from the crushed-up pulp of the South American cassava plant, a woody shrub. Both are used in paleo recipes as alternatives to flour and cornstarch. If you’re using it to on your baby’s sore bottom, try this recipe with some extra ingredients to help soothe.

Baking soda. You thought sodium bicarbonate, otherwise known as baking soda, only had 100 uses. Well, here’s one more: This common pantry item can be used in place of baby powder. Some people even use it as deodorant, applying some to their underarms each morning. It can also deodorize the air. As a matter of fact, I keep one container in my pantry, one under my sink, one in my laundry room and one in the bathroom.

Oat flour. Try this if you’re looking for a slightly coarser powder than the ones mentioned above.

Commercial baby powder alternatives. These products combine the items listed above with essential oils, so the powder smells pretty nice. Just to name a few:

Burt’s Bee’s Baby Dusting Powder
Honeybee Gardens Deodorant Powder
The Honest Company Organic Baby Powder
Nature’s Baby Dusting Powder
Here’s one last reason to consider the all-natural route: Talc is poisonous when inhaled or swallowed. It can cause breathing problems, which is why the American Academy of Pediatrics urges caution when it comes to using talc powder on babies.

If you or a loved one has a diagnosis of ovarian cancer and you or they have used Talcum Powder to dry off around the genital areas for over five years it would be in your best interest to call the Talcum Powder Lawsuit Helpline and speak to one of our talcum powder lawyers

FDA Approves New Ovarian Cancer Drug

The Talcum Powder Lawsuit Helpline has qualified Baby Powder and Shower To Shower lawyers for women who feel their ovarian cancer diagnosis is due to ” dusting Off ” for years with talcum powder products.  The Talcum Powder Lawsuit Helpline continues to keep woman and families updated on the talcum Powder Lawsuit latest news and any new research or news pertaining to ovarian cancer that we think will be helpful to our readers.

We found this  online and feel it is important information for our readers.

FRIDAY, Dec. 19, 2014 (HealthDay News) — The U.S. Food and Drug Administration has approved a new drug to treat advanced ovarian cancer, along with a test to identify patients eligible to receive the drug.

Lynparza (olaparib) belongs to a new class of drugs called poly ADP-ribose polymerase (PARP) inhibitors. The drug is for women who have already received extensive treatment for advanced ovarian cancer associated with defective BRCA genes, according to an FDA news release issued Friday.

“Today’s approval constitutes the first of a new class of drugs for treating ovarian cancer,” Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in the news release.

“Lynparza is approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment,” he said.

Approval of the AstraZeneca drug was based on a clinical trial of almost 140 women with BRCA mutation-associated ovarian cancer. Thirty-four percent of the patients on the drug had partial shrinkage or complete disappearance of their tumors for an average of eight months, the FDA reported.

Nausea, fatigue, vomiting, diarrhea, headache, decreased appetite, joint and muscle pain, and cold-like symptoms were common side effects of the drug. More serious side effects included lung inflammation; the bone marrow cancer acute myeloid leukemia; and myelodysplastic syndrome, a condition where the bone marrow is unable to produce enough functioning blood cells, the FDA said.

Women must undergo a genetic test to confirm BRCA gene mutations before they can be treated with Lynparza. The test to confirm those genes was approved by the FDA in conjunction with the drug.

BRCA genes play a role in repairing damaged DNA. Normally, they work to suppress tumor growth. Women with mutations that cause defective BRCA genes have an increased risk for ovarian and breast cancer. It’s believed that 10 to 15 percent of all ovarian cancer is associated with these mutations, the FDA said.

In 2014, nearly 22,000 American women will be diagnosed with ovarian cancer and more than 14,000 will die from the disease, according to the U.S. National Cancer Institute.

If you or a loved one has a diagnosis of ovarian cancer and has used talcum powder products for years contact the Talcum Powder Lawsuit Helpline.

Liquid Biopsies For Earlier Ovarian Cancer Tracking

The Talcum Powder Lawsuit Helpline continues in one of  it’s missions  to offer the latest news regarding ovarian cancer. We receive dozens of calls on a daily basis from women who feel their use of Talcum Powder products has resulted in their ovarian cancer diagnosis. We continue to connect women with qualified talcum powder ovarian cancer lawyers and offer news we feel will be helpful to these women.

We found this latest news online and hope it will be helpful to our followers.

There is new news about  liquid biopsies offering  hope for earlier treatment and  better tracking of ovarian cancer.

A promising new way to monitor and treat recurrence of ovarian cancer has been identified by researchers a hard-to-detect disease that claims many lives. New research finds liquid biopsies from blood tests and DNA sequencing can detect a return of ovarian cancer long before a tumor reappears.

If you have used Talcum Powder products and suspect an ovarian cancer this may be an option to check out with your doctor.

Researchers at the Mayo Clinic Center for Individualized Medicine have found a promising new way to monitor and treat recurrence of ovarian cancer — a hard-to-detect disease that claims many lives. New research from George Vasmatzis, Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, finds liquid biopsies from blood tests and DNA sequencing can detect a return of ovarian cancer long before a tumor reappears. That could lead to earlier intervention and more effective, individualized treatment. Dr. Vasmatzis’ research on the “Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-free DNA From Ovarian Cancers” is published in the July 20 edition of Scientific Reports.

“With liquid biopsies, we don’t have to wait for tumor growth to get a DNA sample,” says Dr. Vasmatzis. “This important discovery makes it possible for us detect recurrence of the disease earlier than other diagnostic methods. We can repeat liquid biopsies to monitor the progression of the cancer. That gives hope of a better treatment plan over time.”

The study was done on 10 patients in advanced stages of ovarian cancer. Blood was drawn before and after surgery. Investigators compared DNA from the liquid blood biopsies to DNA tissue samples from the tumor, using mate-pair sequencing — an inexpensive whole exome sequencing that can reveal genetic changes that contribute to tumor growth.

“In this study, the blood drawn before and after surgery and the surgical tissue was used to identify DNA fragments with abnormal junctions that can only be seen in this patient’s tumor DNA,” explains Dr. Vasmatzis. “Next-generation mate-pair sequencing was used to identify specific DNA changes of the tumor to create an individualized monitoring panel for liquid biopsy. This allows us to shape treatment to the individual patient rather than using a standard treatment that may not work for everyone.”

When post-surgery DNA matched that of the tumor, patients were later found to have had a recurrence of ovarian cancer. However, when the post-surgery DNA did not match the DNA of the tumor, patients were found to be in remission.

Ovarian cancer has one of the highest death rates of all gynecological cancers, because the tumor often cannot be detected until the late stages. Most patients go into remission after initial treatment, but the tumor returns 75 percent of the time. The next stage of ovarian cancer that develops typically does not respond to chemotherapy. More than 21,000 women in the U.S. were diagnosed with ovarian cancer, and 14,000 women died of the disease in 2015.

We wonder if the 1000’s of women using talcum powder products and the latest research on the link between talcum powder use and ovarian cancer has anything to do with such huge numbers. Many women have used talcum powder for years, especially in the Afro American and Hispanic community. J & J marketed their products to these women and the idea of smelling fresh and clean became a girlfriend to girlfriend positive  in smelling  “sweet and fresh like  Talcum Powder today.”

Talcum Powder- Ovarian Cancer Helpline

The Talcum Powder Lawsuit Helpline has Talcum Powder lawyers filing Talcum Powder lawsuits for women who have gotten ovarian cancer from Talcum Powder. The Talcum Powder Lawsuit Helpline continues to report any recent news regarding the lawsuits and research regarding ovarian cancer. Ovarian cancer is a serious and often fatal disease and we are constantly on the look out for new and important updates that may be of interest to our followers.

We found this article and thought it might be helpful to women. This article discusses some ways to make it easier to find out if you have or are at risk for ovarian cancer.

Testing the  DNA  of a woman should identify the most effective drugs and finds out if other family members are at risk.

Fewer than a third of patients are currently tested, but the team at the Institute of Cancer Research (ICR) in London made it easier for women and increased uptake to 100%.

Experts said the findings were an important step.

The focus of testing is a set of genetic mutations which run in families called BRCA – they cause 15% of the 7,100 ovarian cancers detected in the UK each year.

Knowing if the patient is in the 15% helps improve treatment as some chemotherapy drugs are more effective against tumours caused by BRCA mutations.

And cancer drugs such as PARP inhibitors work only in women with BRCA mutations.

A tumour that is positive for BRCA is also an early warning to other family members that they may be at risk of developing ovarian, breast or prostate cancers.

‘Excellent example’
Testing currently involves getting an appointment with a separate genetics team after being diagnosed by a cancer doctor. The average wait is 12-15 weeks, the researchers say, and only a minority of women go for it.

The ICR team used advances in genetics testing – which is getting faster and cheaper – to offer screening with the original cancer doctor.

Prof Nazneen Rahman, who led the trial, told the BBC News website: “It cuts off all that time on a waiting list and extra consultation. The feedback from patients has been overwhelmingly positive.”

The results of the trial, published in the journal Scientific Reports, showed all patients had screening and got their results in a quarter of the time. It also estimated the National Health Service would save £2.6m a year if it changed the way testing was offered.

Prof Rahman added: “There would be 283 fewer cancers and 77 fewer deaths a year – it really does save lives and money.

“It’s very unusual to get a win-win all round that allows us to help more people but doesn’t cost more.”

It is likely the approach would also work for other cancers, such as those in the breast.

Prof Paul Workman, the chief executive of ICR, said: “Twenty years ago the BRCA2 gene was identified at the ICR. This study is an excellent example of how science such as this can be turned into something very practical that can improve the patient care and save lives. We hope the new model for genetic testing will be rolled out across the NHS.”

Alexandra Holden, from the charity Target Ovarian Cancer, commented: “Any improved access to genetic testing for all women with ovarian cancer is an important step.

“It is essential that all women with ovarian cancer get genetic counseling, as we know from the women with ovarian cancer we support that there can be numerous, complex implications of a test, for all the family.”

Latest Research on Ovarian Cancer

The Talcum Powder Lawsuit Helpline is more then just a network of experienced Talcum Powder Lawsuit Attorneys. We offer ovarian cancer resources and updates that are found online. Below you will find some of the latest research on ovarian cancer. It is now known, that the manufacturers knew that there was a potential link between ovarian cancer and the use of Talcum Powder and Baby Powder. The jury knew it when they gave the family of a talcum powder- ovarian cancer victim $72 million.

We found this page on the latest research and offer it to our followers. We hope this helps.

Ovarian Cancer – Latest Research
Approved by the Cancer.Net Editorial Board, 04/2015

Doctors are working to learn more about ovarian cancer, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the diagnostic and treatment options best for you.

Screening For Ovarian Cancer

There are no currently effective screening methods for the general population. A screening method that estimates a woman’s risk of ovarian cancer by using her age and the results of a yearly CA-125 blood test holds promise for detecting early-stage ovarian cancer. An international study is looking into the role of serial CA-125 screening for ovarian cancer. As explained in Diagnosis, CA-125 is a substance called a tumor marker that is found in higher levels in women with ovarian cancer.

In 2012, the U.S Preventative Services Task Force released a statement saying that for the general population of women with no symptoms, screening for ovarian cancer is not helpful and may lead to harm. However, women at high risk for ovarian cancer due to family history or with a BRCA mutation(s) (see Risk Factors) are recommended to have screening with CA-125 blood tests and transvaginal ultrasound. This approach has not been proven to improve survival or detect cancers at an earlier and more curable stage.

Targeted Therapy For Ovarian Cancer

Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Some targeted therapy is directed towards specific genes that might be found with abnormalities in certain types of epithelial ovarian cancer. For this purpose, ovarian cancer is divided into two groups:  type I and type II.  Type II cancers are the more typical high grade serous cancers, for which standard chemotherapy has been most effective. These tumors typically are diagnosed at later stages and have mutations in TP53 and BRCA genes in the tumor.  Other mutations are rarely seen.

The BRCA mutation, even if only found in the tumor and not in the blood, may increase the effectiveness of a certain classes of drugs such as PARP inhibitors (see below).  Type I tumors include the more rare types of ovarian cancer including low grade serous, endometrioid, clear cell, and mucinous cancers.  These tumors have a variety of mutations including KRAS, BRAF, PI3KCA and PTEN, which have implications for targeted treatment. Clinical trials in these groups are ongoing.

Anti-Angiogenesis Inhibitors For Ovarian Cancer

Drugs called anti-angiogenesis inhibitors block the action of a protein called vascular endothelial growth factor (VEGF). These drugs have been shown to increase the cancer’s response to treatment and delay the time it takes for the cancer to return. VEGF promotes angiogenesis, which is the formation of new blood vessels. Because a tumor needs nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogensis therapies is to “starve” the tumor. Bevacizumab (Avastin), an antibody which binds VEGF and prevents it from being active, has been shown to be effective in ovarian cancer.  FDA approval was recently given in the United States for its use in combination with selected chemotherapy for patients with platinum resistant recurrence.
PARP Inhibitors For Ovarian Cancer

Another class of drugs, called PARP inhibitors, are being evaluated for ovarian cancer.  These drugs act on DNA repair in cancer cells, making it difficult for them to replicate.  The BRCA genes (BRCA1 and BRCA2) are also normally involved in DNA repair, and a mutation in these genes interfere with this pathway function.  PARP inhibitors make it particularly difficult for cells that otherwise have a BRCA mutation to grow and divide.

The PARP inhibitor olaparib (Lynparza) has received FDA approval in the United States for recurrent disease in patients who have the inherited BRCA mutation and who have received three or more lines of chemotherapy.  In the supporting study of 137 patients with a BRCA mutation, 34% of patients experienced shrinkage in tumor for an average of 7.9 months. A very small number of patients developed secondary hematologic (blood) cancers after use of these drugs. Studies are currently underway with other PARP inhibitors, which do not all require the inherited BRCA mutation. These are being tested to see if they can keep the cancer from coming back after chemotherapy. The potential benefits and risks of PARP therapy should be discussed with your doctor.
Many other new targeted treatments are also now in clinical trials. Increasingly, doctors are learning about each patient’s individual tumor’s biology through direct molecular testing. This information may be useful in matching patients with a clinical trial for a specific targeted therapy.  Learn more about the basics of targeted therapy.

Immunotherapy For Ovarian Cancer

Immunotherapy is usually designed to boost the body’s natural defenses to fight the cancer. It uses materials made either by the body or in a laboratory to bolster, target, or restore immune system function. Researchers are currently examining whether drugs called checkpoint inhibitors may boost the immune system’s ability to destroy cancer cells.  Examples of these drugs target CTLA4 or PD-1 and have recently been shown to cause shrinkage in other cancer types such as melanoma, as well as having some activity in patients with ovarian cancer.

Cancer vaccines are another type of immunotherapy currently being tested for ovarian cancer.  In addition, some approaches called “adoptive cell therapy” take killer T cells found as part of the immune system in an individual patient and grow them in the laboratory, train them to attack certain targets such as MUC 16 (CA125) that is found on any ovarian cancer cells, and them give them back intravenously to the patient.  This approach has been tried in patients with hematologic cancers using other targets with some early success, and clinical trials are now opening for ovarian cancer.  Learn more about the basics of immunotherapy.

Hormone Therapy For Ovarian Cancer

Research is underway about the role of estrogen, androgens, and other hormones in ovarian cancer treatment. For treatment of recurrent or later-stage ovarian cancer,  the use of tamoxifen (Nolvadex, Soltamax), aromatase inhibitors, and enzalutamide (Xtandi), a blocker of the androgen receptor, is being considered.

Gene Therapy For Ovarian Cancer

One new area of research is discovering how damaged genes in ovarian cancer cells can be corrected or replaced. Researchers are studying the use of specially designed viruses that carry normal genes into the core of cancer cells and then replace the defective genes with the functional ones.

Supportive Care For Ovarian Cancer

Clinical trials are underway to find better ways of reducing symptoms and side effects of current ovarian cancer treatments, in order to improve a woman’s comfort and quality of life.

We will continue to search the net for ovarian cancer  information to help our clients. Our goal is to offer information that may help